Blackstone Inc.

🇺🇸New York Stock Exchange
Back to all articles
Blackstone Inc. stock analysis BX overview
Somewhat Bullish +35

APGE Stock Surges On Trial Win And $1.3B Blackstone Deal - StocksToTrade

📈 APGE stock surged 46.72% to trade near $132.61 driven by positive Phase 2 data and a major financing announcement.

💊 Zumilokibart mid-dose achieved 65.9% EASI-75 response in atopic dermatitis, showing better efficacy than Dupixent on key benchmarks.

💰 Blackstone Life Sciences provided up to $1.3B in non-dilutive capital ($800M royalty + $500M debt) to fund Phase 3 trials.

📅 Phase 3 registrational trials are scheduled to commence in the second half of 2026.

🏦 Wedbush raised its price target to $135 with an Outperform rating, citing superior historical efficacy potential.

⚖️ Analyst targets are mixed, ranging from Goldman Sachs' $89 Neutral to RBC's $97 speculative risk rating.

💵 Company holds over $1B in cash and short-term investments against only $4.9M in debt as of Q1 2026.

📉 Q1 2026 financials show a net loss of approximately $74M with operating cash flow of -$55.6M.

👥 Dermatologist surveys support a potential $2.5B U.S. revenue view for atopic dermatitis indications.

⚠️ RBC notes that the current share price may already discount much of the core atopic dermatitis story.

🔬 Goldman Sachs downgraded to Neutral after seeing no added efficacy from higher doses versus the mid-dose.

📉 Truist maintains an $81 target and Hold rating, arguing Part B results landed below high expectations.

Bullish Signals
  • Strong Phase 2 APEX Part B data showed the mid-dose of zumilokibart hitting 65.9% EASI-75 with clean safety.
  • Up to $1.3B in non-dilutive financing from Blackstone provides runway through Phase 3 and commercialization.
  • Wedbush raised its price target to $135, citing better historical efficacy than current heavyweights like Dupixent.
  • Company balance sheet is robust with over $1B in cash and short-term investments against minimal debt.
  • Dermatologist survey supports a $2.5B U.S. atopic dermatitis revenue view driven by switching from existing biologics.
Risk Factors
  • RBC analyst survey signals that APGE's current share price already discounts much of the core atopic dermatitis story.
  • Uptake in biologic-naive patients looked weaker according to RBC's dermatologist survey.
  • Goldman Sachs downgraded to Neutral after seeing no added efficacy from a higher dose versus the mid-dose.
  • Truist argues that Part B results landed below high expectations, maintaining a Hold rating with an $81 target.
  • Q1 2026 financials show a net loss of about $74M and operating cash flow of roughly -$55.6M.
Full Analysis
Apogee Therapeutics (NASDAQ: APGE) stock surged approximately 46.72% following positive clinical data from its Phase 2 APEX Part B trial for zumilokibart in atopic dermatitis and a significant financing deal with Blackstone Life Sciences. The mid-dose of the drug achieved a 65.9% EASI-75 response rate with clean safety, demonstrating superior efficacy compared to current standards like Dupixent on key measures. The company secured up to $1.3B in largely non-dilutive financing from Blackstone, comprising $800M in synthetic royalties and up to $500M in senior debt. This capital provides sufficient runway for Phase 3 trials starting in the second half of 2026 and future commercialization across atopic dermatitis, asthma, and eosinophilic esophagitis, significantly reducing dilution risk. Wall Street sentiment remains mixed but constructive, with Wedbush raising its price target to $135 and maintaining an Outperform rating due to the drug's potential as a best-in-class therapy. However, analysts like RBC, Truist, and Goldman Sachs have issued lower targets or Neutral ratings, citing that the current share price may already discount much of the atopic dermatitis opportunity and noting weaker uptake in biologic-naive patients. Financially, Apogee Therapeutics remains a pre-revenue clinical-stage company with Q1 2026 net losses of roughly $74M. Despite this, the balance sheet is robust with over $1B in cash and short-term investments against minimal debt, positioning the firm well for its upcoming registrational trials while maintaining liquidity above 32.